Preferred Label : Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T Cells CTX110;
NCIt synonyms : Allogeneic Anti-CD19 CAR-T Cells CTX110; Allogeneic CRISPR-Cas9-Engineered Anti-CD19 CAR T Cells CTX110; Allogeneic CRISPR-Cas9 Gene-edited CD19-directed CAR T-cells CTX110; Allogeneic Anti-CD19 CAR CRISPR-edited T Cells CTX110;
NCIt definition : A preparation of human allogeneic T-lymphocytes transduced with a chimeric antigen
receptor (CAR) specific for the tumor-associated antigen (TAA) CD19 and gene-edited
with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease
complex to eliminate endogenous TCR, with potential immunostimulating and antineoplastic
activities. Upon introduction into the patient, the allogeneic CRISPR-Cas9 engineered
anti-CD19 CAR T-cells CTX110 recognize and bind to CD19-overexpressing tumor cells.
This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of CD19-positive
tumor cells. Removal of endogenous TCR reduces the risk of graft-versus-host disease
(GvHD). CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell
lineage malignancies.;
Molecule name : CTX101; CTX 110; CTX-110;
NCI Metathesaurus CUI : CL978563;
Origin ID : C165492;
UMLS CUI : C5237220;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
